Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 7;17(7):1285.
doi: 10.3390/nu17071285.

Sufficient Magnesium Intake Reduces Retinal Vein Occlusion Risk: National Health and Nutrition Examination Survey Analysis

Jiwoo Kim  1 , Min Kim  2 , Christopher Seungkyu Lee  3 , Eun Young Choi  2
Affiliations

Sufficient Magnesium Intake Reduces Retinal Vein Occlusion Risk: National Health and Nutrition Examination Survey Analysis

Jiwoo Kim et al. Nutrients. .

Abstract

Background/Objectives: Retinal vein occlusion (RVO) is a major cause of vision loss globally. Although magnesium (Mg) is crucial for vascular health, its association with RVO risk is unknown. Thus, we aimed to further examine this association. Methods: This cross-sectional study included participants of the Korean National Health and Nutrition Examination Survey 2017-2021 aged ≥19 years (n = 16,358). RVO diagnosis was based on fundus imaging or was self-reported. Based on their daily Mg intake, we categorized participants into low (<120 mg), intermediate (men: 120-300 mg; women: 120-400 mg), and sufficient (men: ≥300 mg; women: ≥400 mg) intake groups and compared their characteristics across groups. Results: RVO prevalence was 0.7%. Compared to the non-RVO group, the RVO group was characterized by older individuals, fewer current alcohol consumers, a higher prevalence of hypertension and chronic kidney disease, and a lower intake of fiber, iron, calcium, vitamin E, and Mg. After full adjustment, sufficient Mg intake was significantly associated with a 64% reduced risk of RVO (odds ratio [OR] 0.36, 95% confidence interval [CI] 0.18-0.71, p = 0.003). This association was particularly notable among individuals aged 19-59 years (OR 0.18, 95% CI 0.04-0.82, p = 0.027), those with hypertension (OR 0.29, 95% CI 0.13-0.67, p = 0.003), and those without glaucoma (OR 0.33, 95% CI 0.15-0.71, p = 0.004). Conclusions: Sufficient Mg intake may reduce RVO risk among adults aged <60 years, individuals with hypertension, and those without glaucoma. Further research should validate the benefits of Mg supplementation in preventing RVO.

Keywords: age factor; hypertension; magnesium; national health and nutrition survey; retinal vein occlusion.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowchart of participant selection.
Figure 2
Figure 2
Risk of retinal vein occlusion stratified by daily magnesium intake. Model 1: unadjusted. Model 2: adjusted for age, sex, and BMI. Model 3: adjusted for model 2 covariates plus smoking, alcohol consumption, and comorbidities. Model 4: adjusted for model 3 covariates plus daily nutrient intake. Bold font for p-value indicates statistical significance. OR—odds ratio; CI—confidence interval; BMI—body mass index.
Figure 3
Figure 3
Dose–response analyses of the association between dietary magnesium intake and the risk of retinal vein occlusion. Error bars indicate confidence intervals.
Figure 4
Figure 4
Forest plots of odds ratios for retinal vein occlusion associated with magnesium intake, stratified by age and presence of hypertension and glaucoma. Bold font for p-value and blue error bars in the forest plot indicate statistical significance. OR—odds ratio; CI—confidence interval.
See this image and copyright information in PMC

References

    1. Scott I.U., Campochiaro P.A., Newman N.J., Biousse V. Retinal vascular occlusions. Lancet. 2020;396:1927–1940. doi: 10.1016/S0140-6736(20)31559-2. - DOI - PMC - PubMed
    1. Snider M.J.E., Bheemidi A.R., Muste J.C., Valentim C.C.S., Wu S.Z., Bhatter P., Singh R.P. Meta-Analyses of Two Treatment Regimens for Retinal Vein Occlusion. Ophthalmic Surg. Lasers Imaging Retin. 2023;54:244–250. doi: 10.3928/23258160-20230320-01. - DOI - PubMed
    1. Garweg J.G., Zandi S. Impact of treatment on long-term visual function in retinal vein occlusion-response to the comment on: Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex(R)) in its treatment. Graefe’s Arch. Clin. Exp. Ophthalmol. 2016;254:2479–2480. doi: 10.1007/s00417-016-3459-y. - DOI - PubMed
    1. Ponto K.A., Scharrer I., Binder H., Korb C., Rosner A.K., Ehlers T.O., Rieser N., Grubel N.C., Rossmann H., Wild P.S., et al. Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: Results from the Gutenberg Retinal Vein Occlusion Study. J. Hypertens. 2019;37:1372–1383. doi: 10.1097/HJH.0000000000002057. - DOI - PubMed
    1. Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. J. Ophthalmol. 2014;2014:724780. doi: 10.1155/2014/724780. - DOI - PMC - PubMed

LinkOut - more resources